# Hassabis Leaves the DeepMind Chief Executive Role as Jeff Dean Departs Google

Koray Kavukcuoglu takes over daily operations of the lab behind Gemini, while Hassabis becomes Alphabet chief scientist and concentrates on Isomorphic Labs.

- Published: 2026-08-11T06:26:24.055Z
- Canonical: https://polylog.news/ai/2026-08-11/hassabis-leaves-the-deepmind-chief-executive-role-as-jeff-de
- Publisher: Polylog (AI desk)
- Section: tech
- Sources: [Polylog editors](https://polylog.news), [Axios](https://www.axios.com/2026/08/05/google-deepmind-demis-hassabis-ai), [CNBC](https://www.cnbc.com/2026/08/06/demis-hassabis-google-reshuffle-deepmind-role.html), [Fortune](https://fortune.com/2026/08/05/demis-hassabis-steps-down-google-deepmind-ai-shakeup/)

Demis Hassabis, the Nobel laureate who co-founded DeepMind and ran it through the Gemini era, [is stepping down as chief executive](https://www.axios.com/2026/08/05/google-deepmind-demis-hassabis-ai) and becoming chair of Google DeepMind plus chief scientist of Alphabet. Koray Kavukcuoglu, previously the lab's chief technology officer, takes over daily operations as senior vice president. Hassabis continues to lead Isomorphic Labs, Alphabet's drug-discovery company.

The reshuffle is broader than one title. Jeff Dean, a 27-year Google veteran and most recently chief scientist at Google DeepMind, [is leaving with several colleagues](https://www.cnbc.com/2026/08/06/demis-hassabis-google-reshuffle-deepmind-role.html) to start a public-benefit corporation called Discovery Loop. Losing the person who built much of Google's machine-learning infrastructure at the same moment the founding chief executive moves to a part-time research role is a significant concentration of change in one organization.

Hassabis has framed the move around research rather than management. A widely circulated summary of his remarks [reported by an AI news channel](https://t.me/aipost/7796) has him expecting all human diseases to be curable within twenty years, with Isomorphic Labs as the company meant to deliver it. That is a claim about a scientific timeline made by the person whose company would deliver it, and no peer-reviewed result supports a twenty-year figure. AlphaFold changed structural biology, but structure prediction and end-to-end therapeutic discovery are different problems with different failure modes.

What is verifiable is the organizational fact. Google DeepMind now runs day to day under an engineer rather than its founder, at a point when [Fortune described the changes](https://fortune.com/2026/08/05/demis-hassabis-steps-down-google-deepmind-ai-shakeup/) as a major leadership restructuring across Alphabet's artificial intelligence effort.

## What this means

Alphabet is separating Gemini's product development from long-horizon research, and each side gains something different. Kavukcuoglu inherits a product organization judged on model releases and cloud revenue, which usually shortens research horizons, while Hassabis takes the science mandate to Isomorphic where the payoff is measured in clinical trials rather than benchmark scores. The risk to Alphabet is talent, not strategy: Dean's departure to a new public-benefit corporation shows that senior researchers can now raise capital outside the hyperscalers, and every subsequent exit raises the price Google pays to retain the rest.

## What to watch

- Whether Discovery Loop attracts further senior Google researchers, which would indicate the departures are a pattern rather than one person's decision.
- Whether the next Gemini release cadence changes under Kavukcuoglu, the clearest early read on whether product timelines tighten.
- Any Isomorphic Labs clinical milestone or partnership disclosure, which is the only evidence that would substantiate the drug-discovery claims.